| 赵 峰,李 硕.雷贝拉唑与奥美拉唑治疗胃溃疡合并胃出血疗效对比[J].中国烧伤创疡杂志,2024,(4):324~327. |
| DOI： |
| 中文关键词: 雷贝拉唑 奥美拉唑 铝碳酸镁 胃溃疡 胃出血 |
| 英文关键词:Rabeprazole Omeprazole Hydrotalcite Gastric ulcer Gastric bleeding |
| 基金项目: |
|
| 摘要点击次数: 1656 |
| 全文下载次数: 3830 |
| 中文摘要: |
| 【摘要】 目的 对比分析雷贝拉唑与奥美拉唑治疗胃溃疡合并胃出血的临床疗效。方法 选取 2020 年 4 月至 2022 年 5 月南阳市中心医院收治的 106 例胃溃疡合并胃出血患者作为研究对象, 按照不同治疗方法将其分为雷贝拉唑组 (53 例) 和奥美拉唑组 (53 例), 雷贝拉唑组患者在对症处理的基础上应用雷贝拉唑联合铝碳酸镁治疗, 奥美拉唑组患者在对症处理的基础上应用奥美拉唑联合铝碳酸镁治疗, 对比观察两组患者呕血、便血、上腹部疼痛及发热症状评分与缓解时间以及血清胃泌素 (GAS) 水平、血清胃蛋白酶原 (PG) 水平与不良反应发生情况。结果 治疗后, 雷贝拉唑组患者症状评分以及血清 GAS、PGⅠ、PGⅡ水平均明显低于奥美拉唑组 ( t =8.149、5.684、7.257、7.515, P 均<0.001), PGⅠ/ PGⅡ值明显大于奥美拉唑组 (t = 5.146, P<0.001)。雷贝拉唑组患者呕血、便血缓解时间明显短于奥美拉唑组 (t = 3.789, P<0.001), 上腹部疼痛缓解时间及发热缓解时间与奥美拉唑组无明显差异 (t = 1.511、0.865, P= 0.134、0.389)。治疗期间, 雷贝拉唑组患者不良反应发生率为7.55%, 与奥美拉唑组患者的不良反应发生率 9.43%无明显差异 (χ2 = 0.121, P = 0.727)。结论 与奥美拉唑联合铝碳酸镁相比, 雷贝拉唑联合铝碳酸镁更能快速缓解胃溃疡合并胃出血患者的临床症状, 有效抑制胃肠激素及胃消化液的分泌, 且不良反应较少。 |
| 英文摘要: |
| 【Abstract】 Objective To compare the clinical efficacy of rabeprazole and omeprazole in treating gastric ulcers complicated with gastric bleeding. Methods 106 patients with gastric ulcers complicated with gastric bleeding, admitted to Nanyang Central Hospital from April 2020 to May 2022, were enrolled as research subjects and were divided into the rabeprazole group (n = 53) and the omeprazole group ( n = 53) according to different treatment methods they received. On the basis of symptomatic treatments, patients in the rabeprazole group were treated with rabeprazole combined with hydrotalcite, whereas patients in the omeprazole group were treated with omeprazole combined with hydrotalcite. Scores of symptoms including hematemesis, hematochezia, upper abdominal pain and fever, and their relief times, serum gastrin (GAS) levels, serum pepsinogen (PG) levels, and adverse reaction rates of patients were compared between the two groups. Results After treatment, the symptom scores, levels of serum GAS, PGⅠ, and PGⅡ of patients in the rabeprazole group were significantly lower than those in the omeprazole group (t = 8.149, 5.684, 7.257 and 7.515, all P<0.001). The PGⅠ/ PGⅡ ratio was significantly higher in the rabeprazole group (t = 5.146, P<0.001). The relief time for hematemesis and hematochezia was significantly shorter in the rabeprazole group compared with the omeprazole group ( t = 3.789, P<0.001). There were no significant differences in the relief times for upper abdominal pain and fever between the two groups (t = 1.511 and 0.865,P= 0.134 and 0.389). During the course of treatment, the incidence of adverse reactions in patients in the rabeprazole group was 7.55%, showing no statistically significant difference compared with the corresponding 9.43% in the omeprazole group (χ2 =0.121, P=0.727). Conclusion Compared with omeprazole combined with hydrotalcite, rabeprazole combined with hydrotalcite can relieve the clinical symptoms of patients with gastric ulcers complicated with gastric bleeding more rapidly,effectively inhibit the secretion of gastrointestinal hormones and gastric digestive juices, and lead to fewer adverse reactions. |
|
|
|
|
